Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals’ LNA-modified ASOs to effectively block important immunosuppressive pathway

Written by Petra Hegmann on 26th March 2020. Posted in Client News.

• Previous
• Next